GAMBACORTI PASSERINI, CARLO

GAMBACORTI PASSERINI, CARLO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 281 (tempo di esecuzione: 0.022 secondi).
Titolo Tipologia Data di pubblicazione Autori File
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 01 - Articolo su rivista 2023 Malighetti, FedericaMauri, MarioManghisi, BeatriceInzoli, ElenaRindone, GiovanniCivettini, IvanGuglielmana, VeronicaRamazzotti, DanieleBombelli, SilviaPerego, RobertoPiazza, RoccoMologni, LucaGambacorti-Passerini, Carlo +
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option 01 - Articolo su rivista 2022 Gambacorti Passerini C. +
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study 01 - Articolo su rivista 2022 Gambacorti Passerini C. +
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 01 - Articolo su rivista 2022 Inzoli E.Aroldi A.Piazza R.Gambacorti Passerini C.
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2022 Mologni L.Gambacorti Passerini C. +
Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection 01 - Articolo su rivista 2022 Giardini, ValentinaOrnaghi, SaraGambacorti-Passerini, CarloCasati, MarcoCarrer, AndreaAcampora, EleonoraVasarri, Maria ViolaArienti, FrancescaVergani, Patrizia
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 01 - Articolo su rivista 2022 Cairoli R.Gambacorti Passerini C. +
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data 01 - Articolo su rivista 2021 Gambacorti Passerini C +
Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study 01 - Articolo su rivista 2021 Cavalca, FZambrotta, GPMGambacorti Passerini, CElli, EM +
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 01 - Articolo su rivista 2021 Ramazzotti. , DanieleAngaroni, FabrizioMaspero, DavideGambacorti-Passerini, CarloAntoniotti, MarcoGraudenzi, AlexPiazza, Rocco
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 01 - Articolo su rivista 2021 Aroldi, AGambacorti Passerini, C +
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy 01 - Articolo su rivista 2021 Gambacorti Passerini C. +
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 01 - Articolo su rivista 2021 Gambacorti Passerini C.Aroldi A.Piazza R. +
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma, GGVilla, MMauri, MCrespiatico, IFontana, DMastini, CMagistroni, VCeccon, MRedaelli, SMassimino, LPiazza, RGambacorti Passerini, CMologni, L +
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma G. G.Mologni L.Gambacorti Passerini C. +
Letter to the editor: Sflt-1 and plgf levels in pregnancies complicated by sars-cov-2 infection 01 - Articolo su rivista 2021 Giardini V.Ornaghi S.Acampora E.Vasarri M. V.Arienti F.Gambacorti Passerini C.Carrer A.Vergani P. +
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 01 - Articolo su rivista 2021 Cairoli R.Farina F.Gambacorti Passerini C. +
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias 01 - Articolo su rivista 2021 Gambacorti Passerini C. +
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 01 - Articolo su rivista 2021 Ceccon M.Mologni L.Gambacorti Passerini C. +
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2021 Fontana D.Gambacorti Passerini C.Piazza R.